Key result
Jian-Gan-Xiao-Zhi decoction improves NAFLD in rats by modulating gut microbiota and reducing liver inflammation.
Why the study?
Jian-Gan-Xiao-Zhi decoction has demonstrated beneficial effects on NAFLD, but the mechanisms behind its impact remain unknown.
Does Jian-Gan-Xiao-Zhi decoction improve nonalcoholic fatty liver disease in a high-fat diet-induced rat model?
Does Jian-Gan-Xiao-Zhi decoction improve nonalcoholic fatty liver disease in a high-fat diet-induced rat model?
p-value: p=<0.05
Jian-Gan-Xiao-Zhi decoction ameliorates nonalcoholic fatty liver disease in a rat model by modulating gut microbiota, decreasing gut permeability, and alleviating liver inflammation.
Hypothesis-generating for gut-liver axis therapies in NAFLD; leaves open human translation from this rat model.
BackgroundJian-Gan-Xiao-Zhi decoction (JGXZ), composed of Salvia miltiorrhiza Bunge, Panax notoginseng, Curcuma zedoaria, and other 9 types of herbs, has demonstrated beneficial effects on nonalcoholic fatty liver disease (NAFLD). However, the mechanisms behind JGXZ’s impact on NAFLD remain unknown. MethodsIn this study, a NAFLD rat model induced by a high-fat diet (HFD) received oral treatment of JGXZ (8 or 16 g crude herb/kg) for 8 weeks. The therapeutic effects of JGXZ on NAFLD model rats were investigated through blood lipid levels and pathological liver changes. 16s rRNA analysis was used to study the changes in gut microbiota after JGXZ treatment. The expressions of occludin and tight junction protein 1 (ZO-1) in colon were investigated using immunostaining to study the effects of JGXZ on gut permeability. The anti-inflammatory effects of JGXZ were also studied through measuring the levels of IL-1β, IL-6 and TNF-α in serum and liver.ResultsJGXZ treatment could decrease body weight and ameliorate dyslipidemia in NAFLD model rats. H&E and Oil Red O staining indicated that JGXZ reduced steatosis and infiltration of inflammatory cells into the liver. 16s rRNA analysis exhibited that JGXZ impacted the diversity of gut microbiota, decreasing the Firmicutes to Bacteroidetes ratio and increasing the relative abundance of probiotics, such as Alloprevotella, Lactobacillus, and Turicibacter. Gut permeability evaluation found that the expressions of ZO-1 and occludin in the colon were increased after JGXZ treatment, and inflammation analysis showed decreased levels of IL-1β, IL-6, and TNF-α in the serum and liver after treatment. ConclusionsOur study illustrates that JGXZ ameliorates NAFLD through modulating gut microbiota, decreasing gut permeability, and alleviating liver inflammation.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2020) studied Nonalcoholic fatty liver disease (NAFLD) (n=40). Jian-Gan-Xiao-Zhi decoction (JGXZ) vs. Saline (model group on high-fat diet) was evaluated on Amelioration of NAFLD (body weight gain, liver index, dyslipidemia) (p=<0.05). Jian-Gan-Xiao-Zhi decoction ameliorated nonalcoholic fatty liver disease in a rat model by modulating gut microbiota, decreasing gut permeability, and alleviating liver inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: